Gencurix's study explores GenesWell BCT and Oncotype DX differences

Gencurix, Inc.
Add to favorites

A new study on Frontiers in Oncology comparing GenesWell(TM) BCT, a prognostic multigene test, with Genomic Health's Oncotype DX in patients with early-stage breast cancer

Molecular Diagnostics, GenesWell BCT, Breast Cancer, Prognostic Multigene Test, Clinical Study

Gencurix's study explores GenesWell BCT and Oncotype DX differences

Associated Trend items